Advertisement

GI & Endoscopy

A federally funded study found two different colorectal cancer treatments to have similar efficacy, but a new cost analysis has found there is a significant difference in cost between the two treatment options, according to a Medscape report.

The underwriters participating in the EndoChoice initial public offering are exercising their option to purchase an additional 702,500 shares from the company, as well as 250,000 shares from certain selling stockholders.

Advertisement
Advertisement